Edinburgh‑based Trogenix announced a $95 million Series A to advance its Odysseus platform—AAV vectors carrying Synthetic Super Enhancers that activate therapeutic payloads selectively in cancer cells. Investors including IQ Capital, Eli Lilly, and Cancer Research Horizons financed the round to support first‑in‑human plans, with a glioblastoma IND anticipated and clinical entry forecast for Q1 2026. Trogenix positions the technology as a localized cytotoxic plus immune‑stimulatory approach aimed at aggressive, treatment‑resistant solid tumors.